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Abstract
Introduction: Translation initiation is activated in cancer through increase in eukaryotic initiation factor 4E (eIF4E),
eIF4G, phosphorylated eIF4E-binding protein (p4E-BP1) and phosphorylated ribosomal protein S6 (pS6), and
decreased programmed cell death protein 4 (pdcd4), a translational inhibitor. Further, translation elongation is
deregulated though alterations in eukaryotic elongation factor 2 (eEF2) and eEF2 kinase (eEF2K). We sought to
determine the association of these translational aberrations with clinical-pathologic factors and survival outcomes
in hormone receptor-positive breast cancer.
Methods: Primary tumors were collected from 190 patients with Stage I to III hormone receptor-positive breast
cancer. Expression of eIF4E, eIF4G, 4E-BP1, p4E-BP1 T37/46, p4E-BP1 S65, p4E-BP1 T70, S6, pS6 S235/236, pS6 S240/
244, pdcd4, eEF2 and eEF2K was assessed by reverse phase protein arrays. Univariable and multivariable analyses
for recurrence-free survival (RFS) and overall survival (OS) were performed.
Results: High eEF2, S6, pS6 S240/244, p4E-BP1 T70, and low pdcd4 were significantly associated with node
positivity. Median follow-up for living patients was 96 months.
High p4E-BP1 T36/47, p4E-BP1 S65, p4E-BP1 T70 and 4E-BP1 were associated with worse RFS. High p4E-BP1 T70
and pS6 S235/236, and low pdcd4, were associated with worse OS. In multivariable analysis, in addition to positive
nodes, p4E-BP1 S65 remained a significant predictor of RFS (HR = 1.62, 95% CI = 1.13-2.31; P = 0.008). In addition
to age, pS6 S235/236 (HR = 1.73, 95% CI = 1.03-2.90, P = 0.039), eEF2K (HR = 2.19, 95% CI = 1.35-3.56, P = 0.002)
and pdcd4 (HR = 0.42, 95% CI = 0.25-0.70, P = 0.001) were associated with OS.
Conclusions: Increased pS6, p4E-BP1, eEF2K and decreased pdcd4 are associated with poor prognosis in hormone
receptor-positive breast cancer, suggesting their role as prognostic markers and therapeutic targets.
Introduction
Control of mRNA translation to protein is an important
point of regulation for gene expression. Translation is
deregulated in cancer through a variety of mechanisms
[1]. The most recognized alteration in translation is the
overexpression of eukaryotic initiation factor 4E (eIF4E),
the mRNA 5’cap-binding protein. Cap-dependent
mRNAs initiate translation through interaction with the
cap-dependent initiation complex eIF4F, comprised of
eIF4E, scaffold protein eIF4G, and ATP-dependent heli-
case eIF4A (Figure 1) [2]. eIF4E is the rate limiting step
for cap-dependent translation [3]. eIF4E overexpression
leads to selective translation of a subset of mRNA such
as cyclin D1, Bcl-2, Bcl-xL, and vascular endothelial
growth factor, enhances nucleocytoplasmic transport for
selected mRNA such as cyclin D1 and mediates Akt
activation by upregulating Nijmegen breakage syndrome
protein 1, an Akt pathway activator [1,3-7]. eIF4E over-
expression has transforming activity in fibroblasts and
mammary epithelial cells [8]. In transgenic mice, eIF4E-
overexpression mice develop tumors of various histolo-
gies [9]. Thus, eIF4E also directly acts as an oncogene in
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vivo. Further, formation of the eIF4F complex deter-
mines the sensitivity to chemotherapy, as well as antic-
ancer drugs targeting HER2 and EGFR [10].
Activated translation initiation is essential for the
malignant breast cancer phenotype. eIF4E is overex-
pressed in breast cancer and has been suggested to be
an indicator of poor prognosis [11,12]. Overproduction
of eIF4G, similar to eIF4E, leads to malignant transfor-
mation in vitro [13]. Translation of mRNAs involved in
cell growth, proliferation and bioenergetics were selec-
tively inhibited by reduction in eIF4G1 [14]. Expression
of initiation factor eIF4G is increased in locally
advanced breast cancers (52%) compared to small breast
cancers (11%) (52% vs. 11%, P = 0.0023), and the over-
expression of 4E-BP1 and eIF4G have been proposed to
orchestrate a hypoxia-activated switch from cap-depen-
dent to cap-independent mRNA translation that pro-
motes increased tumor angiogenesis and local tumor
growth [15].
eIF4G1 is also overexpressed in inflammatory breast
cancer, where it reprograms the translational machinery
to increase translation of mRNA with internal ribosome
entry sites (IRES) that promote cell survival and tumor
emboli [16].
eIF4E-binding proteins (4E-BP) compete with eIF4G
for a binding site in eIF4E. The binding of 4E-BP1 to
eIF4E is regulated by phosphorylation; 4E-BP1 hyper-
phosphorylation decreases this binding, increasing eIF4E
availability to engage the cap initiation complex eIF4F.
4E-BP1 is phosphorylated on multiple residues: T37,
T46, S65, T70; phosphorylation at least in part is regu-
lated through PI3K/Akt/mTOR signaling. High levels of
phosphorylated eIF4E-binding protein 1 (p4E-BP1) have
been associated with worse prognosis in several tumor
types including breast cancer [17]. Further, additional
prognostic information is gained by combining assess-
ment of 4E-BPs with eIF4E analysis [18].
Programmed cell death protein 4 (pdcd4) is a tumor
suppressor protein that inhibits breast cancer cell inva-
sion. Pdcd4 inhibits protein translation by binding to
the translation initiation factor eIF4A. Pdcd4 is targeted
for degradation during tumor promotion [19]. Pdcd4
undergoes regulated degradation by b-Trcp after phos-
phorylation at S67 by S6K1 [20].
Ribosomal protein S6 (S6) is a component of the 40S
ribosomal subunit that mediates translation initiation. In
response to mitogenic stimuli, S6 undergoes phosphory-
lation by S6K1 and p90 ribosomal S6 kinases on four
Figure 1 Translational regulation. Translation initiation and elongation is regulated through the expression and phosphorylation status of
several proteins. Arrows represent activation and bars represent inhibition.
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serine residues (S235, S236, S240, and S244); these mod-
ifications potentiate S6 cap-binding activity. S6 phos-
phorylation correlates with increased translation of
mRNA with 5’ terminal oligopyrimidine tracts in some
studies conditions, but not in others. S6 is also proposed
to subsequently undergo casein kinase1-dependent
phosphorylation of S247; phosphorylation of S6 pro-
motes its association with the mRNA cap-binding com-
plex in vitro [21]. Thus S6’s role in translation may be
cell, tissue or context-specific.
Eukaryotic elongation factor-2 kinase (eEF2K) phos-
phorylates and inactivates eukaryotic elongation factor 2
(eEF2), an elongation factor that controls the rate of pep-
tide chain elongation. The activity of eEF2 is increased in
several tumor types including breast cancer [22,23]. eEF2K
also plays a regulatory role in autophagy, and inhibitors of
eEF2K promote cell death [24,25]. eEF2K/eEF2 signaling
may promote cell survival by decreasing energy utilization
on protein synthesis in conditions of stress such as nutri-
ent deprivation or hypoxia and regulating autophagy [25].
Thus, taken together, a significant amount of data has
accumulated suggesting an important role for transla-
tional dysregulation in breast cancer. It remains unclear,
however, which of these alterations are the most signifi-
cant determinants of cancer progression and poor onco-
logic outcomes. We sought to determine the association
of translational regulators with clinical-pathologic fac-




Primary tumors were collected from 190 patients with
Stage I to III hormone receptor-positive breast cancer
treated at Hospital Clinico Universitario de Valencia,
Spain. Tumors were collected from surgical samples,
and tumor content verified by histopathology. Patient
cohort was selected based on hormone receptor-positive
status, availability of adequate frozen tissue, and subse-
quent treatment limited to endocrine therapy. All tissues
were collected after informed consent for future
research. The study was approved by the MD Anderson
Cancer Center Institutional Review Board as well as by
Hospital Clinico Universitario de Valencia. Tumors were
characterized for estrogen receptor (ER) and progester-
one receptor (PR) status by immunohistochemistry. ER/
PR positivity was designated when nuclear staining
occurred in ≥10% of tumor cells. Hormone receptor
positivity was designated when either ER or PR was
positive. All patients were treated with adjuvant endo-
crine therapy (tamoxifen); none received chemotherapy.
HER2 testing was not routinely performed; none of the
patients received HER2-targeted therapy. None of the
patients received neoadjuvant therapy.
Reverse phase protein arrays
Reverse phase protein arrays (RPPA) was performed in
the MD Anderson Cancer Center Functional Proteomics
RPPA Facility as described previously [26,27]. Briefly,
tumor samples homogenized in cold lysis buffer (50
mmol/L HEPES, pH 7.4; 150 mmol/L NaCl; 1% Triton
X-100; 1 mmol/L EGTA; 100 mmol/L NaF; 10 mmol/L
sodium pyrophosphate; 1 mmol/L Na3VO4; 10% gly-
cerol, 1x complete protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN)). After centrifugation,
supernatant was transferred to a fresh tube and protein
concentration was corrected to 1 μg/μL.
The supernatants were subsequently manually diluted
in five-fold serial dilutions with lysis buffer. An Aushon
Biosystems (Burlington, MA, USA) 2470 Arrayer created
1,056 sample arrays on nitrocellulose-coated FAST slides
(Schleicher & Schuell BioScience, Inc., Keene, NH, USA)
from the serial dilutions. Slides were then probed with
primary antibodies including eIF4E, eIF4G, 4E-BP1, p4E-
BP1 T37/46, p4E-BP1 S65, p4E-BP1 T70, S6, pS6 S235/
236, pS6 S240/244, pdcd4, eEF2 and eEF2K (Table 1 in
Additional file 1). The signal was amplified using a Dako-
Cytomation-catalyzed system (Dako North America, Inc.,
Carpinteria, CA, USA). Secondary antibodies were used
as a starting point for amplification. The slides were
scanned, analyzed, and quantitated using MicroVigene
software (VigeneTech Inc., Carlisle, MA, USA) to gener-
ate serial dilution-signal intensity curves for each sample,
and processed by the R package SuperCurve (version
1.01) [28]. A fitted curve (called ‘supercurve’) was plotted
with the signal intensities on the Y-axis and the relative
log2 concentration of each protein on the X-axis using
the nonparametric, monotone increasing B-spline model
[28]. The protein concentrations were derived from the
supercurve for each sample lysate on the slide by curve
fitting and then normalized by median polish. Each pro-
tein measurement was subsequently corrected for loading
as previously described [26].
Statistical analysis
RPPA data from 190 hormone receptor-positive and
Stage I to III patients was median-polish normalized.
The samples were tabulated and described according to
their clinical characteristics. Two sample t tests were
applied to examine the differential expression/phosphor-
ylation of translational factors between stage I and II/III
tumors; their means and standard deviations were also
provided. The same method was used to detect the fac-
tors differentially expressed between node-positive and
-negative patients. To adjust for multiple comparisons,
false discovery rate (FDR) was calculated by using the R
package ‘fdrtool’. Box plots were used to display the sig-
nificant proteins. The FDR threshold of 0.05 was used
for declaration of significance.
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For each of the proteins of interest, a univariable
CoxPH model was established for both recurrence-free
survival (RFS) and overall survival (OS). For multivariable
analysis, a boosting approach (R package CoxBoost) was
employed to develop a Cox proportional hazard model,
and to select predictors. Beside age, nodal status, and T
stage, all other factors were treated as optional covariates.
As the main model complexity parameter, the number of
boosting steps, stepno, was selected with cross-validation
by using cv.CoxBoost. The penalty parameter was chosen
by using optimCoxBoostPenalty. The predictors with
estimated nonzero coefficients were considered to be
incorporated in the final multivariable model. Age, nodal
status and T stage were also retained as mandatory cov-
ariates in the final model because of their clinical signifi-
cance. The final model selection was undertaken based
on a backwards selection procedure, during which all
factors of interest identified by CoxBoost were incorpo-
rated in a full model and then variables were retained
according to their P values (P <0.05).
In order to divide the patients into two groups (high
and low) based on expression levels of factors in the
final multivariate model, a regression tree method of R
package ‘rpart’ was applied to find the best cutoff points
for p4E-BP1 S65, pS6 S235/236, eEF2K and pdcd4. Five-
year survivals for RFS or OS were estimated between
each protein’s high and low expression groups. Logrank
tests were used to evaluate statistical significance.
Kaplan-Meier curves by expression level group were
presented as well. P values less than 0.05 were consid-
ered statistically significant and all tests were two-sided.
All statistical analysis has been done with R statistical
software version 2.11.0.
Results
Association between translational regulators and clinical-
pathologic characteristics
The patient characteristics are shown in Table 1. The
majority (89.7%) of the patients were older than 50
years of age, and the median age was 68 (range 30 to
89). Most patients (64.2%) had node-negative breast
cancer. Most patients had T2 or greater disease (64.2%).
Next, we determined whether expression/phosphoryla-
tion of specific translational factors correlated with clini-
cal-pathologic characteristics. Table S2 in Additional file
1 demonstrates the association between translational
factors and T stage. Only eEF2 expression showed a sig-
nificant association with tumor size (mean expression in
T1: 1.89 arbitrary units vs. mean of T2 to 4 tumors:
2.11, P = 0.016).
Next, we determined association between translational
regulators and axillary nodal status. Higher expression of
eEF2, S6, pS6 S240/244 and p4E-BP1 T70 was significantly
associated with node positivity (FDR <0.2; Figure 2). On
the contrary, lower expression of pdcd4 was associated
with node positivity. Table 3 in Additional file 1 demon-
strates the association between translational regulators
and nodal status.
Translational regulators and recurrence-free and overall
survival
At a median follow-up of 87 months (range 1 to 197
months) there were 47 recurrences and 65 deaths. The
median follow-up for living patients was 96 months. In
order to identify predictive factors, a Cox proportional
hazard model including all of the 14 factors as optional
predictors had been established at first. For each of the
proteins of interest, a univariable CoxPH model results
for both RFS and OS are displayed in Table 2. Interest-
ingly, high p4E-BP1 T36/47, p4E-BP1 S65, p4E-BP1 T70
as well as total 4E-BP1 were associated with worse RFS.
Table 1 Patient and tumor characteristics.
Overall





























aDistribution of grade among patients where grade was available; bfour
patients were estrogen receptor (ER)-negative but progesterone receptor (PR)-
positive, thus hormone receptor-positive.
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This may appear paradoxical as p4E-BP1 would be
expected to increase translation, and increased 4E-BP1
would be expected to decrease it. However, these mar-
kers are not independent from each other for at least
two reasons: increased total 4E-BP1 may be associated
with higher levels of p4E-BP1, and eIF4E levels and
availability may regulate expression of 4E-BP1 [8,29].
A boosting approach (R package CoxBoost) is applied
to determine the corresponding significance. Next, a full
multivariate model has been developed that incorporates
all the factors, which have survived from the boosting
approach and clinic variables based on their statistical
or clinical significance. The final model selection is
undertaken through a backwards selection procedure,
during which the factors of interests are retained if their
P values are less than 0.05 (P <0.05).
When age, nodal status and T stage were added to the
model, in addition to positive nodes, p4E-BP1 S65
remained a significant predictor of RFS (hazard ratio
(HR) = 1.62, 95% confidence interval (CI) = 1.13-2.31,
P = 0.008). The final multivariable models of RFS and
OS are presented in Table 3. The five-year RFS was sig-
nificantly different between patients with high and low
expression of p4E-BP1 S65 (37.5% vs. 88.7%, P ≤0.001,
Figure 3, Table 4). There were no differences between
the expression of the translational regulators tested
between patients who had recurrences early (within two
years) vs. late (after five years).
In addition to age, three translational regulators were
associated with OS on the multivariable model; these
were pS6 S235/236 (HR = 1.73, P = 0.039), eEF2K (HR
= 2.19, P = 0.002) and pdcd4 (HR = 0.42, P = 0.001)
(Table 3). Classification by expression of pS6 S235/236,
eEF2K or pdcd4 resulted in patient groups with signifi-
cantly different five-year OS: pS6 S235/236 high 52.6%
vs. low 87.9%, P <0.001; eEF2K high 79.0% vs. low
85.9%, P = 0.0424; pdcd4 high 91.5% vs. low 74.2%: P =
0.0021 (Figure 3). The five-year survival estimates and
logrank test results are listed in Table 4.
Discussion
A significant amount of data has accumulated suggest-
ing an important role for translational dysregulation in
many cancer lineages, including breast cancer. It
remained unclear, however, which of these alterations
are the most significant determinants of cancer progres-
sion and poor patient outcomes. We sought to deter-
mine the association of translational regulators with
clinical-pathologic factors and survival outcomes in hor-
mone receptor-positive breast cancer. We found that
high eEF2, S6, pS6 S240/244, p4E-BP1 T70, and low
pdcd4 were significantly associated with node positivity.
High p4E-BP1 T36/47, p4E-BP1 S65, p4E-BP1 T70 as
well as total 4E-BP1 were associated with worse RFS.
High p4E-BP1 T70 and pS6 S235/236, and low pdcd4,
were associated with worse OS. In the multivariable
analysis, in addition to positive nodes, high p4E-BP1 S65
remained a significant predictor of lower RFS. High pS6
S235/236, eEF2K and low pdcd4 were associated with
lower OS. These results confirm that translational dysre-
gulation plays an important role in breast cancer pro-
gression and relapse suggesting a role for these as
prognostic markers as well as therapeutic targets.
Our results support the role of PI3K/mTOR pathway
inhibitors for breast cancer treatment in HR-positive
breast cancer. The PI3K/mTOR signaling pathway
Figure 2 Proteins differentially expressed (FDR <0.2) by nodal status in hormone receptor-positive patients.
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controls phosphorylation of 4E-BP1 and S6K, and S6K1
also phosphorylates S6, and has been proposed to phos-
phorylate EF2K and pdcd4, controlling the activity of S6
and EF2K, and protein stability of pdcd4 [20,30-32].
S6K1 also regulates ERa activation through S167 phos-
phorylation [33], adding to the growing evidence that
there is cross-talk between ER and PI3K/mTOR
Table 2 Univariate analysis of RFS and OS for hormone
receptor-positive breast cancer patients.
Recurrence-free survival
Variable HR 95% CI P value FDR
Translational regulator
p4E-BP1 S65 1.51 1.08-2.11 0.02 0.09
p4E-BP1 T36/47 1.49 1.05-2.12 0.03 0.09
4E-BP1 1.66 1.04-2.65 0.04 0.09
p4E-BP1 T70 1.38 1.00-1.90 0.05 0.10
pS6 S235/236 1.37 0.81-2.31 0.23 0.27
pS6 S240/244 1.23 0.83-1.83 0.30 0.29
eIF4G 1.33 0.77-2.30 0.30 0.30
Pdcd4 0.81 0.52-1.26 0.34 0.31
eIF4E 1.12 0.75-1.67 0.58 0.43
S6 0.96 0.67-1.37 0.82 0.52
eEF2K 1.04 0.70-1.55 0.83 0.52
eEF2 0.98 0.59-1.61 0.93 0.55
Age at diagnosis 1.01 0.98-1.04 0.64
Nodal Status
Negative 1
Positive 2.789 1.55-5.03 <0.01
T Stage
T1 1
T2-4 1.339 0.71-2.52 0.37
Overall survival
Variable HR 95% CI FDR
Translational regulator
Pdcd4 0.62 0.42-0.91 0.0155 0.06
p4E-BP1 T70 1.30 0.98-1.71 0.0662 0.12
pS6 S235/236 1.40 0.90-2.18 0.1369 0.14
eEF2 1.27 0.82-1.95 0.2852 0.15
4EBP1 1.22 0.78-1.91 0.3801 0.16
eEF2K 1.15 0.82-1.62 0.4093 0.16
p4E-BP1 S65 1.15 0.82-1.60 0.4144 0.16
S6 1.14 0.83-1.55 0.4192 0.16
pS6 S240/244 1.14 0.81-1.60 0.4484 0.16
p4E-BP1 T36/47 1.13 0.81-1.56 0.4670 0.16
eIF4E 0.94 0.68-1.31 0.7162 0.22
eIF4G 0.98 0.61-1.55 0.9142 0.27
Age at diagnosis 1.05 1.03-1.08 <0.01
Nodal status
Negative 1
Positive 2.05 1.25-3.35 <0.01
T Stage
T1 1
T2-T4 1.36 0.79-2.34 0.26
CI, confidence interval; FDR, false discovery rate; HR, hazard ratio.
Table 3 Multivariable analysis of RFS and OS for
hormone receptor-positive breast cancer patients.
Recurrence-free survival
Variable HR 95% CI P value
Age at diagnosis 1.00 0.97-1.03 0.951
Nodal status
Negative 1
Positive 3.08 1.66-5.73 <0.001
T stage
T1 1
T2-4 1.31 0.66-2.58 0.439
p4E-BP1 S65 1.62 1.13-2.31 0.008
Overall survival
Variable HR 95% CI P value
Age at diagnosis 1.04 1.01-1.07 0.003
Nodal status
Negative
Positive 1.29 0.75-2.23 0.355
T stage
T1
T2-4 1.02 0.58-1.81 0.945
pS6 S235/236 1.73 1.03-2.90 0.039
eEF2K 2.19 1.35-3.56 0.002
Pdcd4 0.42 0.25-0.70 0.001
CI, confidence interval; HR, hazard ratio.









High 8 7 37.5% (15.3%,
91.7%)






High 11 6 52.6% (26.1%,
100%)
Low 177 59 87.9% (82.7%,
88.8%)
0.0001
eEF2K High 126 51 79.0% (71.8%,
86.9%)
Low 62 14 85.9% (77.3%,
95.5%)
0.0424
Pdcd4 High 78 16 91.5% (85.2%,
98.3%)
Low 110 49 74.2% (66.2%,
83.4%)
0.0021
CI, confidence interval; OS, overall survival; RFS, recurrence-free survival.
Meric-Bernstam et al. Breast Cancer Research 2012, 14:R138
http://breast-cancer-research.com/content/14/5/R138




Figure 3 Kaplan-Meier analysis of recurrence-free and overall survival. (A) Recurrence-free survival of the entire cohort. (B) Overall survival
of the entire cohort. (C) Recurrence-free survival in patients by p4E-BP1 S65 expression. High: p4E-BP1 S65 >3.162, Low: p4E-BP1 S65 ≤3.162
(arbitrary units). (D) Overall survival of patients by pS6 S235/236 expression levels. High: pS6 S235/236 >2.75, Low: pS6 S235/236 ≤2.75. (E)
Overall survival of patients by pdcd4 expression levels. High: pdcd4 >2.357, Low: pdcd4 ≤2.357. (F) Overall of patients by eEF2K expression levels.
High: eEF2K >2.248, Low: eEF2K ≤2.248.
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signaling. Our results are consistent with that of Miller
et al., who have shown that in 64 hormone receptor-
positive breast cancer patients, a baseline signature of
PI3K pathway activation is predictive of poor outcome
after adjuvant endocrine therapy [34]. Recently, ER-posi-
tive tumors with long-term estrogen deprivation have
been shown to exhibit increased PI3K/mTOR signaling
[34]. Preclinical studies have demonstrated that the anti-
tumor efficacy of tamoxifen, fulvestrant as well as estro-
gen deprivation can be enhanced with inhibition of
PI3K/mTOR signaling [1]. A phase II trial of tamoxifen
with and without the rapamycin analog everolimus has
shown significant improvement in progression-free sur-
vival (PFS) in hormone receptor-positive patients [35]. A
phase II neoadjuvant trial of letrozole with or without
everolimus showed greater inhibition of cell proliferation
(Ki-67) with the everolimus combination at two weeks,
as well as a greater clinical response rate [35]. Recently,
the exciting data from the phase III BOLERO-2 trial
was released, demonstrating a significantly greater PFS
with the combination of exemestane and everolimus
compared with exemestane alone [36]. Studies are
ongoing with endocrine therapy in combination with
new inhibitors of PI3K, Akt and PI3K/mTOR dual
inhibitors.
There are several approaches to inhibit translation in
preclinical development. As a proof of concept, in pre-
vious work we have shown that eIF4E siRNA knockdown
inhibits cancer cell growth in a variety of breast cancer
cell subtypes [29]. Graff et al. have shown that eIF4E
downregulation with second-generation antisense oligo-
nucleotides reduces in vivo tumor growth in a PC-3 pros-
tate cancer model and MDA-MB-231 breast cancer
model [37]. A phase I trial of antisense oligonucleotides
targeting eIF4E has recently been completed [38]. eIF4E-
binding motif peptides can also interfere with eIF4E-
eIF4G binding, translation initiation, cell cycle, and survi-
val, providing proof of concept that eIF4E-binding small-
molecule inhibitors may have utility in cancer therapy
[39,40]. A 4E-BP1-based peptide fused to a GnRH agonist
was shown to be taken up by GnRHRI-expressing ovarian
cancer cells and inhibit growth in vitro and in vivo [41].
Moerke et al. identified inhibitors of the eIF4E/eIF4G
interaction in a high-throughput screen [42]. The most
potent compound exhibited in vitro activity against mul-
tiple cancer cell lines and appeared to have preferential
effect on transformed cells [42]. Cencic et al. reported
that eIF4E:eIF4G interaction inhibitors can reverse
tumor chemoresistance in lymphoma models [43].
Another potential approach to inhibit translation is by
interfering with eIF4E binding to the 7-methyl guano-
sine cap or by interfering with eIF4E binding to the
multidomain adaptor protein eIF4G, thus interfering
with assembly of the translation initiation complex
eIF4F. Kentsis et al. reported that the antiviral guano-
sine analog ribovirin binds to eIF4E at the site used by
the 7-methyl guanosine cap, competing with eIF4E bind-
ing and disrupting the transport and translation of
mRNAs regulated by eIF4E [44]. Thus, translation initia-
tion is actively being pursued as a therapeutic target. As
activation of translation initiation is a common integral
pathway for the malignant phenotype, these approaches
may hold promise for a variety of tumor types.
Pdcd4 has been reported to inhibit protein translation
by binding to the translation initiation factor eIF4A [45].
As pdcd4 undergoes regulated degradation by b-Trcp
after phosphorylation at S67 by S6K1 [20], PI3K/mTOR
pathway inhibitors may increase pdcd4 expression at
least in some cancer cell lines. However, targeting eIF4E
directly may provide an alternate strategy for pdcd4-low
tumors. Pateamine A, a marine natural product with
potent antiproliferative and immunosuppressive activ-
ities, was also found to inhibit protein translation, inhi-
biting the eukaryotic eIF4A family of RNA helicases
[46]. Des-methyl, des-amino pateamine A (DMDA-
PatA), a structurally simplified analogue of pateamine A,
was recently shown to have potent antiproliferative
activity against a wide variety of human cancer cell lines
[47]. However, it is of note that pdcd4 has other tumor-
suppressive functions reported such as inhibiting AP-1
transactivation [48], and thus pdcd4’s antitumor effect
may not be limited to its effects on translation.
eEF2K is phosphorylated and inhibited by SAPK (JNK)
(on S359), RSK and S6K1 (on S366), and phosphorylated
and activated by AMPK (on S398) [49]. Thus eEF2K
integrates a variety of diverse signaling pathways, and
potentially may be targeted through different strategies.
Of note, insulin signaling and serum stimulation causes
downregulation of eEF2 phosphorylation and eEF2K
activity, and this is blocked by rapamycin [50]. High
doses of temsirolimus are accompanied by a rapid
increase in phosphorylation of eEF2, but this may
involve a S6K1-independent mechanism as it appears to
not correlate with S6K1 activity or eEF2K S366 phos-
phorylation [51]. Further study is needed to determine
the effect of clinically relevant doses of PI3K/mTOR
pathway inhibitors in vivo, and their effect on eEF2K
low- and high-expressing hormone receptor-positive
breast cancers. NH125, a derivative of 2-methylimidazo-
lium iodide has been identified as a potent and relatively
specific inhibitor of EF2K; it was shown to have in vitro
anticancer activity against cell lines of a variety of tumor
lineages including breast cancer [24]. Thus, EF2K/EF2
activity may hold promise as a novel therapeutic target
in hormone receptor-positive breast cancer.
Our study has some limitations. All patients in this
study received endocrine therapy. Thus, it is not possi-
ble to determine whether p4E-BP1, pS6, eEF2K and
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pdcd4 are associated with prognosis or whether they are
associated with endocrine therapy resistance. Patients
received adjuvant tamoxifen; however, the exact dura-
tion of adjuvant treatment with tamoxifen, and compli-
ance with the medication, is unknown. Further work is
needed to determine whether these markers are also
prognostic in patients who received aromatase inhibi-
tors. We do not have detailed information on locoregio-
nal management including radiation therapy, and sites
of relapse including locoregional recurrence, thus we are
unable to dissect the role of translational regulators on
locoregional control. We did not have information on
comorbidities and cause of death, thus we are able to
determine recurrence-free survival and overall survival
but not disease-specific survival. Information on treat-
ment after relapse was also not available. Further work
is also ongoing to determine the intratumoral heteroge-
neity and reproducibility of these markers, and to transi-
tion these markers to alternate platforms such
immunohistochemistry and multiplex proteomics assay
such as Luminex or ELISA that may be used clinically
to identify patients who would have a poor prognosis if
treated with endocrine therapy alone. Another limitation
of our study is that we do not have transcriptional pro-
filing data from the same patients; this is especially rele-
vant as eIF4E mRNA was shown to be prognostic in
luminal B cases, and not in other subtypes [52]. It will
also be important to determine how our biomarkers
correlate with other RNA profile-based molecular tools
to predict prognosis including those that are currently
in clinical use such as Oncotype DX (Genomic Health,
Inc., Redwood City, CA, USA) [53] and MammaPrint
(Agendia Inc., Irvine, CA, USA) [54,55], as well as those
in clinical development such as the PAM50 intrinsic
subtype [56]. To obtain a cohort of patients treated with
endocrine therapy only and with adequate follow-up, we
elected a cohort of patients who was treated prior to
these tools became widely utilized. Oncotype DX, Mam-
maPrint and PAM50 were developed to identify patients
that will have good prognosis with endocrine therapy
alone, or alternately those patients that are at higher
risk of relapse and thus may be offered chemotherapy
followed by endocrine therapy. However, assessment of
p4E-BP1, pS6, eEF2K and pdcd4 may have additional
utility as these biomarkers may not only have prognostic
implications, by providing biological insights. Further
study is needed to determine whether these biomarkers
may be used to guide specific targeted therapy selection.
Conclusions
In summary, increased pS6, p4E-BP1, eEF2K and
decreased pdcd4 are associated with poor prognosis in
hormone receptor-positive breast cancer. Further study is
needed to determine the clinical utility of these as
prognostic or predictive markers. Our results provide
further support for a role for PI3K/mTOR pathway inhi-
bitors in the treatment of hormone receptor-positive
breast cancer. The best approach to personalize treat-
ment in hormone receptor-positive breast cancer patients
with translational aberrations warrants further study.
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